Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
IMGN's Cash to Debt is ranked higher than
96% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. IMGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
IMGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.39  Med: No Debt Max: 50356.33
Current: No Debt
0.39
50356.33
Equity to Asset -0.28
IMGN's Equity to Asset is ranked lower than
94% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. IMGN: -0.28 )
Ranked among companies with meaningful Equity to Asset only.
IMGN' s Equity to Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.73 Max: 0.95
Current: -0.28
-0.28
0.95
F-Score: 3
Z-Score: -4.98
M-Score: 33.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -206.37
IMGN's Operating margin (%) is ranked lower than
60% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. IMGN: -206.37 )
Ranked among companies with meaningful Operating margin (%) only.
IMGN' s Operating margin (%) Range Over the Past 10 Years
Min: -447.86  Med: -116.56 Max: -58.16
Current: -206.37
-447.86
-58.16
Net-margin (%) -239.42
IMGN's Net-margin (%) is ranked lower than
61% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. IMGN: -239.42 )
Ranked among companies with meaningful Net-margin (%) only.
IMGN' s Net-margin (%) Range Over the Past 10 Years
Min: -448.24  Med: -116.63 Max: -49.69
Current: -239.42
-448.24
-49.69
ROA (%) -52.80
IMGN's ROA (%) is ranked lower than
72% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. IMGN: -52.80 )
Ranked among companies with meaningful ROA (%) only.
IMGN' s ROA (%) Range Over the Past 10 Years
Min: -52.8  Med: -35.78 Max: -17.46
Current: -52.8
-52.8
-17.46
ROC (Joel Greenblatt) (%) -661.86
IMGN's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. IMGN: -661.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IMGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -661.86  Med: -323.04 Max: -150
Current: -661.86
-661.86
-150
Revenue Growth (3Y)(%) 67.10
IMGN's Revenue Growth (3Y)(%) is ranked higher than
92% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. IMGN: 67.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IMGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.3  Med: 17 Max: 123.4
Current: 67.1
-36.3
123.4
EBITDA Growth (3Y)(%) -13.40
IMGN's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. IMGN: -13.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IMGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.2  Med: 5.05 Max: 282.6
Current: -13.4
-71.2
282.6
EPS Growth (3Y)(%) -9.30
IMGN's EPS Growth (3Y)(%) is ranked lower than
56% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. IMGN: -9.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IMGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -77.5  Med: 2.15 Max: 290.7
Current: -9.3
-77.5
290.7
» IMGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

IMGN Guru Trades in Q3 2015

Jim Simons 393,440 sh (New)
PRIMECAP Management 12,867,483 sh (unchged)
» More
Q4 2015

IMGN Guru Trades in Q4 2015

PRIMECAP Management 12,867,483 sh (unchged)
Jim Simons 38,040 sh (-90.33%)
» More
Q1 2016

IMGN Guru Trades in Q1 2016

Ken Fisher 244,225 sh (New)
PRIMECAP Management 12,867,483 sh (unchged)
Jim Simons Sold Out
» More
Q2 2016

IMGN Guru Trades in Q2 2016

Paul Tudor Jones 63,300 sh (New)
Jim Simons 1,967,140 sh (New)
Ken Fisher 253,701 sh (+3.88%)
PRIMECAP Management 10,113,629 sh (-21.40%)
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:BSTC, NAS:AGTC, NAS:EDGE, NAS:FOMX, NAS:IMMU, NAS:PTCT, NAS:RXDX, NAS:SQNM, OTCPK:NICXF, NAS:ESPR, NAS:CNCE, NAS:IDRA, NAS:NVIV, NAS:CYAD, NAS:CRVS, NAS:MNOV, OTCPK:GNIXF, NAS:CYNA, NAS:NLNK, NAS:PRTK » details
Traded in other countries:IMU.Germany,
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: mirvetuximab soravtansine, or IMGN853, coltuximab ravtansine, formerly SAR3419, and IMGN529 and have reported preclinical data for IMGN779, which expected to be next clinical-stage compound. IMGN779 is the first ADC utilizing GN technology. The compound with ADC technology is Roche's marketed product, Kadcyla (ado-trastuzumab emtansine). Eight other ADC compounds and one non-ADC, or 'naked' antibody product candidate, are in clinical testing. The Company's current partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company, or Lilly, Novartis Institutes for BioMedical Research, Inc., or Novartis, the Roche Group, Sanofi and Takeda. Its competitors include pharmaceutical companies and other biotechnology firms, Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. Its patent portfolio had approximately 659 issued patents and approximately 645 pending patent applications all over the world. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.

Ratios

vs
industry
vs
history
P/S 4.19
IMGN's P/S is ranked higher than
75% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. IMGN: 4.19 )
Ranked among companies with meaningful P/S only.
IMGN' s P/S Range Over the Past 10 Years
Min: 2.82  Med: 14.89 Max: 97.63
Current: 4.19
2.82
97.63
Current Ratio 4.85
IMGN's Current Ratio is ranked higher than
53% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. IMGN: 4.85 )
Ranked among companies with meaningful Current Ratio only.
IMGN' s Current Ratio Range Over the Past 10 Years
Min: 0.71  Med: 8.11 Max: 60.86
Current: 4.85
0.71
60.86
Quick Ratio 4.83
IMGN's Quick Ratio is ranked higher than
54% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. IMGN: 4.83 )
Ranked among companies with meaningful Quick Ratio only.
IMGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 7.81 Max: 60.86
Current: 4.83
0.71
60.86
Days Sales Outstanding 0.63
IMGN's Days Sales Outstanding is ranked higher than
99% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. IMGN: 0.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.63  Med: 19.78 Max: 88.26
Current: 0.63
0.63
88.26

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.60
IMGN's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. IMGN: -3.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17  Med: -7.5 Max: -0.7
Current: -3.6
-17
-0.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.28
IMGN's Price/Median PS Value is ranked higher than
90% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. IMGN: 0.28 )
Ranked among companies with meaningful Price/Median PS Value only.
IMGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.35 Max: 10.58
Current: 0.28
0.22
10.58
Earnings Yield (Greenblatt) (%) -119.51
IMGN's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. IMGN: -119.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IMGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -195.17  Med: 0 Max: 0
Current: -119.51
-195.17
0

More Statistics

Revenue (TTM) (Mil) $60.00
EPS (TTM) $ -1.65
Beta1.84
Short Percentage of Float28.81%
52-Week Range $2.53 - 16.59
Shares Outstanding (Mil)87.08

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Jun17 Jun18 Jun19
Revenue (Mil $) 21 32 152
EPS ($) -1.85 -1.96 -0.86
EPS w/o NRI ($) -1.85 -1.96 -0.86
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for IMGN

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) Surge on Jan 31 2015 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
IMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Aug 17 2016
ImmunoGen Announces Departure of Chief Development Officer Aug 09 2016
IMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Aug 09 2016
ImmunoGen Announces Departure of Chief Development Officer Aug 09 2016
ImmunoGen (IMGN) Reports Wider-than-Expected Loss in Q4 Aug 05 2016
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences Aug 05 2016
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences Aug 05 2016
Edited Transcript of IMGN earnings conference call or presentation 4-Aug-16 12:00pm GMT Aug 04 2016
ImmunoGen Inc Earnings Call scheduled for 8:00 am ET today Aug 04 2016
Q4 2016 ImmunoGen Inc Earnings Release - 06:30 am ET Aug 04 2016
ImmunoGen reports 4Q loss Aug 04 2016
ImmunoGen reports 4Q loss Aug 04 2016
ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly... Aug 04 2016
IMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 04 2016
ImmunoGen Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Provides Quarterly... Aug 04 2016
Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings? Aug 02 2016
5 Hated Earnings Stocks You Should Love Aug 02 2016
These 5 Stocks Under $10 Are Set to Soar Higher Jul 28 2016
ETF’s with exposure to ImmunoGen, Inc. : July 25, 2016 Jul 25 2016
ImmunoGen, Inc. Announces Conference Call to Discuss Its Fourth Quarter and Fiscal Year 2016... Jul 21 2016
Autohome, ImmunoGen Lead Friday’s 52-Week Low Club Jul 15 2016
ImmunoGen, CVR Top Thursday’s 52-Week Low Club Jul 14 2016
CVR Refining, ImmunoGen Join Wednesday’s 52-Week Low Club Jul 13 2016
The Montana Tile Worker Who Fought Daughter’s Rare Kidney Cancer Jun 29 2016
ImmunoGen Announces Pricing of $100 Million Offering of 4.50% Convertible Senior Notes Due 2021 Jun 15 2016
ImmunoGen Announces Proposed $100 Million Offering of Convertible Senior Notes Due 2021 Jun 13 2016
ImmunoGen Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetuximab Soravtansine in... May 18 2016
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences May 12 2016
ImmunoGen Reports Third Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update May 12 2016
ImmunoGen Appoints Mark J. Enyedy as President and Chief Executive Officer May 12 2016
ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMGN779 for Acute Myeloid... May 12 2016
ImmunoGen reports 3Q loss Apr 29 2016
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors Mar 21 2016
ImmunoGen reports 2Q loss Jan 29 2016
ImmunoGen reports 1Q loss Oct 27 2015
ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Event on September 18, 2015 Sep 17 2015
Webcast of the ImmunoGen, Inc. Analyst & Investor Event on September 18, 2015 Sep 17 2015
ImmunoGen reports 4Q loss Jul 31 2015
ImmunoGen skids after disclosing drug development setbacks Apr 27 2015
ImmunoGen reports 3Q loss Apr 24 2015
ImmunoGen lands big licensing deal with Japan's Tekada Mar 23 2015
ImmunoGen beats Street 2Q forecasts Jan 30 2015
Ahead of the Bell: ImmunoGen shares tumble Dec 19 2014
ImmunoGen misses Street 1Q forecasts Oct 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)